Villa Maria Pia, Rizzoli Alessandra, Rabasco Jole, Vitelli Ottavio, Pietropaoli Nicoletta, Cecili Manuela, Marino Alessandra, Malagola Caterina
Neuroscience, Mental Health and Sense Organs Department, Paediatric Sleep Disorder Centre, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University, Rome, Italy.
Neuroscience, Mental Health and Sense Organs Department, Paediatric Sleep Disorder Centre, Sant'Andrea Hospital, Faculty of Medicine and Psychology, "Sapienza" University, Rome, Italy.
Sleep Med. 2015 Jun;16(6):709-16. doi: 10.1016/j.sleep.2014.11.019. Epub 2015 Mar 16.
The objectives of this study were to confirm the efficacy of rapid maxillary expansion in children with moderate adenotonsillar hypertrophy in a larger sample and to evaluate retrospectively its long-term benefits in a group of children who underwent orthodontic treatment 10 years ago.
After general clinical examination and overnight polysomnography, all eligible children underwent cephalometric evaluation and started 12 months of therapy with rapid maxillary expansion. A new polysomnography was performed at the end of treatment (T1). Fourteen children underwent clinical evaluation and Brouilette questionnaire, 10 years after the end of treatment (T2).
Forty patients were eligible for recruitment. At T1, 34/40 (85%) patients showed a decrease of apnea-hypopnea index (AHI) greater than 20% (ΔAHI 67.45% ± 25.73%) and were defined responders. Only 6/40 (15%) showed a decrease <20% of AHI at T1 and were defined as non-responders (ΔAHI -53.47% ± 61.57%). Moreover, 57.5% of patients presented residual OSA (AHI > 1 ev/h) after treatment. Disease duration was significantly lower (2.5 ± 1.4 years vs 4.8 ± 1.9 years, p <0.005) and age at disease onset was higher in responder patients compared to non-responders (3.8 ± 1.5 years vs 2.3 ± 1.9 years, p <0.05). Cephalometric variables showed an increase of cranial base angle in non-responder patients (p <0.05). Fourteen children (mean age 17.0 ± 1.9 years) who ended orthodontic treatment 10 years previously showed improvement of Brouilette score.
Starting an orthodontic treatment as early as symptoms appear is important in order to increase the efficacy of treatment. An integrated therapy is needed.
本研究的目的是在更大样本中证实快速上颌扩弓对中度腺样体扁桃体肥大儿童的疗效,并对一组10年前接受正畸治疗的儿童进行回顾性评估其长期益处。
在进行全面临床检查和夜间多导睡眠图检查后,所有符合条件的儿童均接受头影测量评估,并开始为期12个月的快速上颌扩弓治疗。治疗结束时(T1)进行一次新的多导睡眠图检查。治疗结束10年后(T2),对14名儿童进行临床评估和布罗伊lette问卷调查。
40名患者符合入选标准。在T1时,34/40(85%)的患者呼吸暂停低通气指数(AHI)下降大于20%(ΔAHI 67.45%±25.73%),被定义为反应者。只有6/40(15%)的患者在T1时AHI下降<20%,被定义为无反应者(ΔAHI -53.47%±61.57%)。此外,57.5%的患者治疗后仍存在阻塞性睡眠呼吸暂停(AHI>1次/小时)。反应者患者的病程明显较短(2.5±1.4年 vs 4.8±1.9年,p<0.005),疾病发病年龄高于无反应者(3.8±1.5年 vs 2.3±1.9年,p<0.05)。头影测量变量显示无反应者患者的颅底角增加(p<0.05)。10年前结束正畸治疗的14名儿童(平均年龄17.0±1.9岁)的布罗伊lette评分有所改善。
为提高治疗效果,尽早开始正畸治疗很重要。需要综合治疗。